Cell-based therapies have revolutionized cancer treatment in recent years, particularly through the use of CAR T therapies. These treatments involve modifying immune cells to target and destroy cancer cells. However, one of the main challenges with current CAR T therapies is the reliance on the patient’s own immune cells, which can lead to delays, high costs, and variability in treatment outcomes.
To address these challenges, researchers are now exploring the use of universal donor cells for CAR T therapy. These donor cells, which are genetically modified T cells from healthy donors, can be used for multiple patients, offering a more efficient and cost-effective approach to treatment. A recent study published in The New England Journal of Medicine demonstrated the potential of universal cell therapy in overcoming some of the key barriers in cell-based cancer treatment.
In the study, healthy donor T cells were gene-edited to make them compatible with any patient. These modified cells were expanded, frozen, and stored as an off-the-shelf product that could be used for multiple patients. Eleven patients were treated with cells from a single donor cell bank, and the results were promising. All patients achieved remission by day 28, with nine reaching deep remission and proceeding to a stem-cell transplant. However, two patients with residual disease required palliative care.
While most patients experienced expected side effects, such as cytokine release syndrome and opportunistic infections, the study showed that universal gene-edited T-cell therapy could be delivered rapidly and at scale. This represents a significant advancement in making cancer treatment more accessible and affordable for a larger number of patients.
Moving forward, the focus will be on improving the durability of universal cell therapy and reducing the need for intensive conditioning. The goal is to transition from individualized to universal cell therapies, offering a ready-to-use option that can potentially cure patients without the need for subsequent transplantation.
Overall, the development of universal CAR T cell therapies using gene-edited donor T cells holds great promise for the future of cancer treatment. By overcoming key barriers of cost, delay, and access, these therapies have the potential to transform the landscape of cell-based cancer therapy, making it faster, more affordable, and accessible to a broader range of patients.
